Satire: Health Minister Announces New Plan to Grow Private Health Sector

The Public-Private Partnership That Requires Your Urinary Tract

On Monday, Health Minister Simeon Brown unveiled what he called a “bold, innovative step” to grow New Zealand’s private health sector, announcing a new initiative to “legalise ketamine to all under 35s” and “give it out to anyone under 30 for free.”

Officials stressed the policy is not a drug giveaway. It is, they said, “a targeted economic intervention,” designed to “unlock capacity” and “reduce pressure” on the public health system by ensuring the public health system has less to do and more to explain.

“New Zealanders have been asking for reform,” Brown said. “This is reform. It’s just not the kind anyone was expecting.”

The Minister framed the plan as a pragmatic response to familiar constraints: workforce shortages, waitlists, and a public health sector that keeps insisting it’s fine while making the kind of eye contact that suggests it is not, in fact, fine.

Ketamine, Brown noted, is already used internationally in medical contexts. In the United States and Europe, a ketamine-derived medicine (esketamine) has been approved for treatment-resistant depression under strict clinical supervision, with dosing and monitoring requirements designed to keep patients safe and, importantly, indoors.

“But here in New Zealand,” Brown continued, “we do things differently. We believe in delivering healthcare where people are: on couches, at festivals, in the passenger seat of a Toyota Corolla.”

The Government insists the policy is motivated by wellbeing. Critics argue it is motivated by arithmetic.

Under the proposal—currently described as a “discussion document,” which is how you announce a decision without the inconvenience of being accountable for it—ketamine would be made broadly available to younger New Zealanders, with a “starter pack” distributed through pharmacies, student health services, and what officials referred to as “community-based supply partners.” The Minister did not clarify what those partners are, but did confirm they are “very committed to harm minimisation” and “open late.”

Public health experts have raised concerns, pointing out that widespread recreational ketamine use is associated with serious urinary tract harm, including ketamine-induced cystitis, a condition linked to bladder pain, urgency, reduced bladder capacity, and sometimes irreversible damage.

Brown acknowledged these concerns and said they were, in fact, “the whole point.”

“By giving ketamine for free,” he explained, “we’re not encouraging misuse. We’re strategically rebalancing demand.”

He paused, as if waiting for the room to catch up.

“What the public sector can’t fund,” he continued, “the private sector can invoice.”

The logic is elegant in its simplicity. If young people develop chronic bladder issues, they will require urology appointments, investigations, and procedures—services that are already under pressure in the public system and often easier to access faster through private pathways, provided you have the money, the insurance, or a relative willing to call it an early inheritance.

In other words: a pipeline.

“Right now,” Brown said, “the private health sector is underutilised. People only go private when they have to—hip replacements, cataracts, the occasional morally injured knee. We want to normalise private healthcare earlier. We want to build lifelong customer relationships.”

A reporter asked whether this amounted to manufacturing illness to stimulate market growth.

Brown rejected this characterization.

“We’re not manufacturing anything,” he said. “New Zealanders are perfectly capable of damaging their own bodies. We’re simply removing barriers and streamlining the process.”

The Minister compared the policy to other public health initiatives, such as subsidised prescriptions.

“This is basically Pharmac,” he said, “but for bladder deterioration.”

Officials also emphasised that ketamine is a controlled substance in New Zealand and that current law tightly regulates controlled drugs—an observation some critics described as “interesting” given that the entire plan involves un-regulating it.

Still, the Government urged calm, noting that ketamine has legitimate medical uses and that “responsible administration” is key. They did not clarify how responsibility would be administered at scale to tens of thousands of under-30s, but said a public education campaign was being developed, tentatively titled “Mindful K: Listen to Your Bladder.”

When pressed on the health impacts, Brown said the Government had consulted evidence.

“There are studies,” he said, “and we respect them. Some even show the condition can improve if ketamine use stops.”

He then announced Phase Two: incentives to ensure it doesn’t.

“Obviously,” he said, “behaviour change is difficult. That’s why we’re also launching a loyalty programme.”

Under the loyalty programme, New Zealanders who demonstrate consistent ketamine use would receive “priority access” to private diagnostic services through participating providers, along with a commemorative reusable cup and a voucher for a discounted MRI, redeemable after your first emergency department visit.

The Government insists this is not privatisation. It is “partnership.”

“This is about choice,” Brown said. “We’re expanding the range of ways New Zealanders can experience healthcare: waiting, paying, or doing both.”

Opposition parties called the policy reckless. Civil liberties groups described it as “a bold new approach to consent.” Health advocates asked why the Government was not instead investing directly in public capacity.

Brown responded by reaffirming the Government’s commitment to strengthening the health system.

“And we are strengthening it,” he said. “The private part.”

He added that the plan would also create jobs, including in urology, radiology, and what he described as “bladder-adjacent industries.”

In the final minutes of the press conference, officials attempted to return the narrative to wellbeing, noting that mental health remains a priority and that ketamine-derived therapies overseas have shown benefits under controlled clinical models.

This reassurance landed awkwardly, mainly because the overseas models involve strict monitoring, medical screening, and supervised administration, whereas the New Zealand model—at least as described on Monday—appears to involve a pharmacist asking if you’d like a tote bag.

That looseness, however, has been welcomed by at least one sector of the health system.

“This is actually a very stable condition, from a planning perspective,” said the chief executive of a large private healthcare provider, speaking on condition of being quoted confidentially. “Ketamine-related bladder damage doesn’t really resolve, which is helpful. It means we’re not dealing with seasonal demand or one-off interventions. These are long-term patients.”

He described ketamine-induced cystitis as “predictable,” “non-curative,” and “resource-intensive,” three qualities the private sector traditionally associates with sustainability.

“There’s no silver bullet,” he said. “Stopping ketamine can slow progression, but it doesn’t undo the damage. Once the bladder’s compromised, you’re managing symptoms for years. Sometimes decades. From an investment standpoint, that’s reassuring.”

Medical literature supports this optimism. Studies of regular recreational ketamine use consistently show that a substantial proportion of users develop chronic lower urinary tract symptoms, reduced bladder capacity, fibrosis, and inflammation that often persist even after cessation. Treatment focuses on pain control, catheterisation, bladder instillations, and, in severe cases, reconstructive surgery or cystectomy. There is no established cure. There is only management.

The CEO confirmed his organisation was already responding.

“We’re expanding urology capacity,” he said. “More clinics, more imaging, more procedure rooms. We’re also training staff to recognise ketamine-related pathology earlier, which helps patients enter the system sooner.”

Asked whether this amounted to planning around preventable harm, he disagreed.

“Young people are going to experiment,” he said. “We just want to be ready when experimentation turns into a chronic billing relationship.”

He added that bladder conditions were “underrated” from a growth perspective.

“They’re not glamorous,” he said. “But they’re persistent. And persistence is what keeps the lights on.”

The Health Minister declined to comment on the remarks but reiterated that the Government’s focus was on “choice” and “innovation.” He stressed that ketamine has legitimate uses and that individuals would be responsible for how they engage with it.

The private sector, meanwhile, appears grateful for the clarity.

“For once,” the CEO said, “there’s no ambiguity about outcomes. This isn’t a maybe. This is a pipeline.”

For students, this may be the most practical lesson of their degree: some substances don’t just alter your consciousness, they alter your balance sheet. And when a condition has no cure, no quick fix, and no public capacity, it doesn’t disappear.

It simply changes hands.

Preferably early.